Catumaxomab (Removab®, Fresenius) is a trifunctional rat-mouse hybrid monoclonal antibody co-binding to the epithelial cell adhesion molecule (EpCAM) and to CD3 antigen. The double epitope specificity allows in forcing the interaction between cancer cells expressing EpCAM, and activated T cells. The third binding via the Fc-region of catumaxomab with Fcγ receptors allows direct involvement of immune accessory cells in killing the target.
KeywordsOvarian Cancer Systemic Inflammatory Response Syndrome Peritoneal Carcinomatosis Malignant Ascites Epithelial Cell Adhesion Molecule
- 1.Catumaxomab (Removab®) EMEA WC500051809 Annex I September 2011Google Scholar
- 3.Linke R, Klein A, Seimetz D (2010) Catumaxomab. Clinical development and future directions. MAbs 2:129–136Google Scholar
- 5.Catumaxomab (Removab®) EMEA WC500051808 Assessment Report Feb 2009Google Scholar
- 6.Patriarca C, Macchi RM, Marschner AK et al (2012) Epithelial cell adhesion molecule expression (CD326) in cancer: a short review Cancer Treatment Rev 38:68-75Google Scholar
- 9.Eskander RN, Tewar KS (2012) Emerging treatment options for management of malignant ascites in patients with ovarian cancer. Intern J Women’s Health 4:395–404Google Scholar